Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice

Circulation

Volumn 110, Issue 5, 2004, Pages 540-545

  Lewis, Katherine E ^a   Kirk, Elizabeth A ^a   McDonald, Thomas O ^a   Wang, Shari ^a   Wight, Thomas N ^b   O'Brien, Kevin D ^a   Chait, Alan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOPE HEART INSTITUTE   (United States)

Author keywords

Amyloid; Cholesterol; Diet; Inflammation; Lipoproteins

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOGLYCAN; SATURATED FATTY ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL INTAKE; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, DIETARY; DIET, ATHEROGENIC; EXTRACELLULAR MATRIX PROTEINS; FEMALE; LIPOPROTEINS, HDL; MICE; MICE, KNOCKOUT; PROTEOGLYCANS; RECEPTORS, LDL; SERUM AMYLOID A PROTEIN; SERUM AMYLOID P-COMPONENT; TRIGLYCERIDES;

EID: 3543084598     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000136819.93989.E1     Document Type: Article

References (34)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Jousilahti P, Salomaa V, Rasi V, et al. The association of C-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease: baseline findings of the PAIS project. Atherosclerosis. 2001;156:451-456.
3. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
4. Erren M, Reinecke H, Junker R, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999;19:2355-2363.
5. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439-1441.
6. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-2534.
7. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
8. Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002;99:13043-13048.
9. Hayat S, Raynes JG. Acute phase serum amyloid A protein increases high density lipoprotein binding to human peripheral blood mononuclear cells and an endothelial cell line. Scand J Immunol. 2000;51:141-146.
10. Artl A, Marsche G, Pussinen P, et al. Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int J Biochem Cell Biol. 2002;34:370-381.
11. Badolato R, Wang JM, Stornello SL, et al. Serum amyloid A is an activator of PMN antimicrobial functions: induction of degranulation, phagocytosis, and enhancement of anti-Candida activity. J Leukoc Biol. 2000;67:381-386.
12. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest. 1996;26:427-435.
13. Camejo G. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv Lipid Res. 1982;19:1-53.
14. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
15. Skalen K, Gustafsson M, Rydberg E, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750-754.
16. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
17. Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993;162:131-146.
18. Leinonen E, Hurt-Camejo E, Wiklund O, et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003;166:387-394.
19. Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003;27:443-449.
20. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res. 1990;31:1149-1172.
21. Liao F, Lusis AJ, Berliner JA, et al. Serum amyloid A protein family: differential induction by oxidized lipids in mouse strains. Arterioscler Thromb. 1994;14:1475-1479.
22. Godenir NL, Jeenah MS, Coetzee GA, et al. Standardisation of the quantitation of serum amyloid A protein (SAA) in human serum. J Immunol Methods. 1985;83:217-225.
23. Cabana VG, Reardon CA, Wei B, et al. SAA-only HDL formed during the acute phase response in apoA-I+/+ and apoA-/- mice. J Lipid Res. 1999;40:1090-1103.
24. Balmer P, McMonagle F, Alexander J, et al. Experimental erythrocytic malaria infection induces elevated serum amyloid P production in mice. Immunol Lett. 2000;72:147-152.
25. Hurt-Camejo E, Camejo G, Sartipy P. Measurements of proteoglycan- lipoprotein interaction by gel mobility shift assay. Methods Mol Biol. 1998;110:267-279.
26. Olin KL, Potter-Perigo S, Barrett PH, et al. Biglycan, a vascular proteoglycan, binds differently to HDL(2) and HDL(3): role of apoE. Arterioscler Thromb Vasc Biol. 2001;21:129-135.
27. Kunjathoor VV, Chiu D, O'Brien KD, et al. Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:462-468.
28. O'Brien KD, Olin KL, Alpers CE, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 1998;98:519-527.
29. Crawford RS, Kirk E, Rosenfeld ME, et al. Dietary antioxidants inhibit the development of fatty streak lesions in the LDL-receptor deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:1506-1513.
30. Bouchard FM. Acceleration of the Movat pentachrome one stain by heat. Stain Technol. 1967;42:257-259.
31. Szalai AJ. The biological functions of C-reactive protein. Vasc Pharmacol. 2002;39:105-107.
32. Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem. 1999;274:7172-7181.
33. Ancsin JB, Kisilevsky R. Serum amyloid A peptide interactions with glycosaminoglycans: evaluation by affinity chromatography. Methods Mol Biol. 2001;171:449-456.
34. Hoff HF, Jackson RL, Gotto AM Jr. Apolipoprotein localization in human atherosclerotic arteries. Adv Exp Med Biol. 1976;67:109-120.